Top

Published in:

01-05-2024 | Colorectal Cancer | Review Article

The role of SWI/SNF complexes in digestive system neoplasms

Authors: Hanyun Liang, Xin Zheng, Xiao Zhang, Yan Zhang, Jie Zheng

Published in: Medical Oncology | Issue 5/2024

Abstract

Chromatin remodeling is a critical step in the DNA damage response, and the ATP-dependent chromatin remodelers are a group of epigenetic regulators that alter nucleosome assembly and regulate transcription factor accessibility to DNA, preventing genomic instability and tumorigenesis caused by DNA damage. The SWI/SNF chromatin remodeling complex is one of them, and mutations in the gene encoding the SWI/SNF subunit are frequently found in digestive tumors. We review the most recent literature on the role of SWI/SNF complexes in digestive tumorigenesis, with different SWI/SNF subunits playing different roles. They regulate the biological behavior of tumor cells, participate in multiple signaling pathways, interact with multiple genes, and have some correlation with the prognosis of patients. Their carcinogenic properties may help discover new therapeutic targets. Understanding the mutations and defects of SWI/SNF complexes, as well as the underlying functional mechanisms, may lead to new strategies for treating the digestive system by targeting relevant genes or modulating the tumor microenvironment.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Zheng RS, Zhang SW, Sun KX, et al. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi. 2023. https://doi.org/10.3760/cma.j.cn112152-20220922-00647.CrossRefPubMed

Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020. https://doi.org/10.1016/S1470-2045(20)30073-5.CrossRefPubMedPubMedCentral

Cao W, Chen H-D, Yu Y-W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021. https://doi.org/10.1097/CM9.0000000000001474.CrossRefPubMed

Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022. https://doi.org/10.1097/CM9.0000000000002108.CrossRefPubMedPubMedCentral

Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020. https://doi.org/10.1111/his.13975.CrossRefPubMedPubMedCentral

Jf F. WHO Classification of digestive tumors: the fourth edition. Ann Pathol. 2011. https://doi.org/10.1016/j.annpat.2011.08.001.CrossRef

Kang MA, Lee J-S. A newly assigned role of CTCF in cellular response to broken DNAs. Biomolecules. 2021. https://doi.org/10.3390/biom11030363.CrossRefPubMedPubMedCentral

Ribeiro-Silva C, Vermeulen W, Lans H. SWI/SNF: Complex complexes in genome stability and cancer. DNA Repair. 2019. https://doi.org/10.1016/j.dnarep.2019.03.007.CrossRefPubMed

10.

Moison C, Chagraoui J, Caron M-C, et al. Zinc finger protein E4F1 cooperates with PARP-1 and BRG1 to promote DNA double-strand break repair. Proc Natl Acad Sci U S A. 2021. https://doi.org/10.1073/pnas.2019408118.CrossRefPubMedPubMedCentral

11.

Vaicekauskaitė I, Sabaliauskaitė R, Lazutka JR, et al. The emerging role of chromatin remodeling complexes in ovarian cancer. IJMS. 2022. https://doi.org/10.3390/ijms232213670.CrossRefPubMedPubMedCentral

12.

Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 2011. https://doi.org/10.1038/cr.2011.32.CrossRefPubMedPubMedCentral

13.

Wang W, Côté J, Xue Y, et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 1996;15:5370–82.CrossRefPubMedPubMedCentral

14.

Pulice JL, Kadoch C. Composition and function of Mammalian SWI/SNF chromatin remodeling complexes in human disease. Cold Spring Harb Symp Quant Biol. 2016. https://doi.org/10.1101/sqb.2016.81.031021.CrossRefPubMed

15.

Mittal P, Roberts CWM. The SWI/SNF complex in cancer—biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020. https://doi.org/10.1038/s41571-020-0357-3.CrossRefPubMedPubMedCentral

16.

Romero OA, Sanchez-Cespedes M. The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases. Oncogene. 2014. https://doi.org/10.1038/onc.2013.227.CrossRefPubMed

17.

Mashtalir N, D’Avino AR, Michel BC, et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. Cell. 2018. https://doi.org/10.1016/j.cell.2018.09.032.CrossRefPubMedPubMedCentral

18.

Sima X, He J, Peng J, et al. The genetic alteration spectrum of the SWI/SNF complex: The oncogenic roles of BRD9 and ACTL6A. PLoS ONE. 2019. https://doi.org/10.1371/journal.pone.0222305.CrossRefPubMedPubMedCentral

19.

Drage MG, Tippayawong M, Agoston AT, et al. Morphological features and prognostic significance of ARID1A-deficient esophageal adenocarcinomas. Arch Pathol Lab Med. 2017. https://doi.org/10.5858/arpa.2016-0318-OA.CrossRefPubMed

20.

Lowenthal BM, Nason KS, Pennathur A, et al. Loss of ARID1A expression is associated with DNA mismatch repair protein deficiency and favorable prognosis in advanced stage surgically resected esophageal adenocarcinoma. Hum Pathol. 2019. https://doi.org/10.1016/j.humpath.2019.09.004.CrossRefPubMed

21.

Schallenberg S, Bork J, Essakly A, et al. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma. BMC Cancer. 2020. https://doi.org/10.1186/s12885-019-6425-3.CrossRefPubMedPubMedCentral

22.

Zhou Z, Huang D, Yang S, et al. Clinicopathological significance, related molecular changes and tumor immune response analysis of the abnormal SWI/SNF complex subunit PBRM1 in gastric adenocarcinoma. Pathol Oncol Res. 2022. https://doi.org/10.3389/pore.2022.1610479.CrossRefPubMedPubMedCentral

23.

Glückstein M-I, Dintner S, Arndt TT, et al. Comprehensive immunohistochemical study of the SWI/SNF complex expression status in gastric cancer reveals an adverse prognosis of SWI/SNF deficiency in genomically stable gastric carcinomas. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13153894.CrossRefPubMed

24.

Zhu YP, Sheng LL, Wu J, et al. Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer. Hum Pathol. 2018. https://doi.org/10.1016/j.humpath.2018.04.003.CrossRefPubMed

25.

Shih-Chiang Huang, Chen K-H, Ng K-F, et al. Dedifferentiation-like tubular and solid carcinoma of the stomach shows phenotypic divergence and association with deficient SWI/SNF complex. Virchows Arch. 2022. https://doi.org/10.1007/s00428-022-03288-6

26.

Tsuruta S, Kohashi K, Yamada Y, et al. Solid-type poorly differentiated adenocarcinoma of the stomach: Deficiency of mismatch repair and SWI/SNF complex. Cancer Sci. 2020. https://doi.org/10.1111/cas.14301.CrossRefPubMedPubMedCentral

27.

Huang S, Ng K, Yeh T, et al. The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression. Histopathology. 2020. https://doi.org/10.1111/his.14117.CrossRefPubMedPubMedCentral

28.

Huang S-C, Ng K-F, Chang IY-F, et al. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes. PLoS One. 2021. https://doi.org/10.1371/journal.pone.0245356

29.

Zhang Z, Li Q, Sun S, et al. Clinicopathological and prognostic significance of SWI/SNF complex subunits in undifferentiated gastric carcinoma. World J Surg Onc. 2022. https://doi.org/10.1186/s12957-022-02847-0.CrossRef

30.

Sasaki T, Kohashi K, Kawatoko S, et al. Tumor progression by epithelial-mesenchymal transition in ARID1A- and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma. Virchows Arch. 2022. https://doi.org/10.1007/s00428-021-03261-9.CrossRefPubMed

31.

Mochizuki K, Kawai M, Odate T, et al. SMARCB1/INI1 is diagnostically useful in distinguishing α-fetoprotein-producing gastric carcinoma from hepatocellular carcinoma. Anticancer Res. 2018;38:6865.CrossRefPubMed

32.

Sen M, Wang X, Hamdan FH, et al. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells. Clin Epigenetics. 2019. https://doi.org/10.1186/s13148-019-0690-5.CrossRefPubMedPubMedCentral

33.

Yang Z, Huang D, Meng M, et al. BAF53A drives colorectal cancer development by regulating DUSP5-mediated ERK phosphorylation. Cell Death Dis. 2022. https://doi.org/10.1038/s41419-022-05499-w.CrossRefPubMedPubMedCentral

34.

Ke S-B, Qiu H, Chen J-M, et al. MicroRNA-202-5p functions as a tumor suppressor in colorectal carcinoma by directly targeting SMARCC1. Gene. 2018. https://doi.org/10.1016/j.gene.2018.08.064.CrossRefPubMed

35.

Melloul S, Mosnier J-F, Masliah-Planchon J, et al. Loss of SMARCB1 expression in colon carcinoma. CBM. 2020. https://doi.org/10.3233/CBM-190287.CrossRef

36.

Wang J, Andrici J, Sioson L, et al. Loss of INI1 expression in colorectal carcinoma is associated with high tumor grade, poor survival, BRAFV600E mutation, and mismatch repair deficiency. Hum Pathol. 2016. https://doi.org/10.1016/j.humpath.2016.04.018.CrossRefPubMedPubMedCentral

37.

Villatoro TM, Ma C, Pai RK. Switch/sucrose nonfermenting nucleosome complex–deficient colorectal carcinomas have distinct clinicopathologic features. Hum Pathol. 2020. https://doi.org/10.1016/j.humpath.2020.03.009.CrossRefPubMed

38.

Ahadi MS, Fuchs TL, Clarkson A, et al. SWI/SNF complex (SMARCA4, SMARCA2, INI1/SMARCB1) deficient colorectal carcinomas are strongly associated with microsatellite instability: An incidence study in 4508 colorectal carcinomas. Histopathology. 2022. https://doi.org/10.1111/his.14612.CrossRefPubMed

39.

Agaimy A, Daum O, Märkl B, et al. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid carcinomas of the gastrointestinal tract: a series of 13 cases highlighting mutually exclusive loss of SMARCA4 and SMARCA2 and frequent Co-inactivation of SMARCB1 and SMARCA2. Am J Surg Pathol. 2016. https://doi.org/10.1097/PAS.0000000000000554.CrossRefPubMedPubMedCentral

40.

Agaimy A, Daum O, Michal M, et al. Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases. Virchows Arch. 2021. https://doi.org/10.1007/s00428-021-03032-6.CrossRefPubMedPubMedCentral

41.

Fang J-Z, Li C, Liu X-Y, et al. Hepatocyte-specific Arid1a deficiency initiates mouse steatohepatitis and hepatocellular carcinoma. PLoS ONE. 2015. https://doi.org/10.1371/journal.pone.0143042.CrossRefPubMedPubMedCentral

42.

Midorikawa Y, Yamamoto S, Tatsuno K, et al. Accumulation of molecular aberrations distinctive to hepatocellular carcinoma progression. Can Res. 2020. https://doi.org/10.1158/0008-5472.CAN-20-0225.CrossRef

43.

Zhang F-K, Ni Q-Z, Wang K, et al. Targeting USP9X–AMPK axis in ARID1A-Deficient hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2022. https://doi.org/10.1016/j.jcmgh.2022.03.009.CrossRefPubMedPubMedCentral

44.

Zhang L, Sun T, Wu X-Y, et al. Delineation of a SMARCA4-specific competing endogenous RNA network and its function in hepatocellular carcinoma. World J Clin Cases. 2022. https://doi.org/10.12998/wjcc.v10.i29.10501

45.

Chen Z, Lu X, Jia D, et al. Hepatic SMARCA4 predicts HCC recurrence and promotes tumour cell proliferation by regulating SMAD6 expression. Cell Death Dis. 2018. https://doi.org/10.1038/s41419-017-0090-8.CrossRefPubMedPubMedCentral

46.

Guerrero-Martínez JA, Reyes JC. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer. Sci Rep. 2018. https://doi.org/10.1038/s41598-018-20217-3.CrossRefPubMedPubMedCentral

47.

Wang P, Song X, Cao D, et al. Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell Death Dis. 2020. https://doi.org/10.1038/s41419-020-2289-3.CrossRefPubMedPubMedCentral

48.

Hong SH, Son KH, Ha SY, et al. Nucleoporin 210 serves a key scaffold for SMARCB1 in liver cancer. Can Res. 2021. https://doi.org/10.1158/0008-5472.CAN-20-0568.CrossRef

49.

Cai X, Zhou J, Deng J, Chen Z. Prognostic biomarker SMARCC1 and its association with immune infiltrates in hepatocellular carcinoma. Cancer Cell Int. 2021. https://doi.org/10.1186/s12935-021-02413-w.CrossRefPubMedPubMedCentral

50.

Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012. https://doi.org/10.1038/nature11547.CrossRefPubMedPubMedCentral

51.

Okamura R, Kato S, Lee S, et al. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2019-000438.CrossRefPubMedPubMedCentral

52.

Botta GP, Kato S, Patel H, et al. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight. 2021. https://doi.org/10.1172/jci.insight.150453.CrossRefPubMedPubMedCentral

53.

Shain AH, Giacomini CP, Matsukuma K, et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci U S A. 2012. https://doi.org/10.1073/pnas.1114817109.CrossRefPubMed

54.

Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res. 2011. https://doi.org/10.3109/07435800.2010.525085.CrossRefPubMed

55.

Han X, Chen W, Chen P, et al. Aberration of ARID1A is associated with the tumorigenesis and prognosis of sporadic nonfunctional pancreatic neuroendocrine tumors. Pancreas. 2020. https://doi.org/10.1097/MPA.0000000000001535.CrossRefPubMed

56.

Sotozono H, Kanki A, Yasokawa K, et al. Value of 3-T MR imaging in intraductal papillary mucinous neoplasm with a concomitant invasive carcinoma. Eur Radiol. 2022. https://doi.org/10.1007/s00330-022-08881-6.CrossRefPubMed

57.

Kimura Y, Fukuda A, Ogawa S, et al. ARID1A maintains differentiation of pancreatic ductal cells and inhibits development of pancreatic ductal adenocarcinoma in mice. Gastroenterology. 2018. https://doi.org/10.1053/j.gastro.2018.03.039.CrossRefPubMedPubMedCentral

58.

Ferri-Borgogno S, Barui S, McGee AM, et al. Paradoxical role of AT-rich interactive domain 1A in restraining pancreatic carcinogenesis. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12092695.CrossRefPubMed

59.

Tessier-Cloutier B, Schaeffer DF, Bacani J, et al. Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas. Histopathology. 2020. https://doi.org/10.1111/his.14096.CrossRefPubMedPubMedCentral

60.

Yamamoto T, Kohashi K, Yamada Y, et al. Relationship between cellular morphology and abnormality of SWI/SNF complex subunits in pancreatic undifferentiated carcinoma. J Cancer Res Clin Oncol. 2022. https://doi.org/10.1007/s00432-021-03860-8.CrossRefPubMedPubMedCentral

61.

L L, Y L, Y G, et al. Potential roles of PBRM1 on immune infiltration in cholangiocarcinoma. Int J Clin Exp Pathol 2020;13(10):2661–2676.

62.

Zheng S, Zhu Y, Zhao Z, et al. Liver fluke infection and cholangiocarcinoma: a review. Parasitol Res. 2017. https://doi.org/10.1007/s00436-016-5276-y.CrossRefPubMedPubMedCentral

63.

Namjan A, Techasen A, Loilome W, et al. ARID1A alterations and their clinical significance in cholangiocarcinoma. PeerJ. 2020. https://doi.org/10.7717/peerj.10464.CrossRefPubMedPubMedCentral

64.

Fukunaga Y, Fukuda A, Omatsu M, et al. Loss of Arid1a and Pten in pancreatic ductal cells induces Intraductal Tubulopapillary Neoplasm via the YAP/TAZ pathway. Gastroenterology. 2022. https://doi.org/10.1053/j.gastro.2022.04.020.CrossRefPubMed

65.

Wang W, Friedland SC, Guo B, et al. ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas. Gut. 2019. https://doi.org/10.1136/gutjnl-2017-315541.CrossRefPubMed

66.

Baldi S, Zhang Q, Zhang Z, et al. ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression. J Cell Mol Med. 2022. https://doi.org/10.1111/jcmm.17590.CrossRefPubMedPubMedCentral

67.

Niedermaier B, Sak A, Zernickel E, et al. Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response. Sci Rep. 2019. https://doi.org/10.1038/s41598-019-54757-z.CrossRefPubMedPubMedCentral

68.

Dong X, Song S, Li Y, et al. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut. 2022. https://doi.org/10.1136/gutjnl-2020-322660.CrossRefPubMed

69.

Zhu Y, Li K, Yan L, et al. miR-223-3p promotes cell proliferation and invasion by targeting Arid1a in gastric cancer. Acta Biochim Biophys Sin (Shanghai). 2020. https://doi.org/10.1093/abbs/gmz151.CrossRefPubMed

70.

Bala P, Singh AK, Kavadipula P, et al. Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer. Oncogene. 2021. https://doi.org/10.1038/s41388-020-01537-z.CrossRefPubMed

71.

Li R, Li Y, Qin H, et al. ACTL6A promotes the proliferation of esophageal squamous cell carcinoma cells and correlates with poor clinical outcomes. OTT Volume. 2021. https://doi.org/10.2147/OTT.S288807.CrossRef

72.

Wei Z, Xu J, Li W, et al. SMARCC1 enters the nucleus via KPNA2 and plays an oncogenic role in bladder cancer. Front Mol Biosci. 2022. https://doi.org/10.3389/fmolb.2022.902220.CrossRefPubMedPubMedCentral

73.

Lüönd F, Sugiyama N, Bill R, et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021. https://doi.org/10.1016/j.devcel.2021.11.006.CrossRefPubMed

74.

Erfani M, Zamani M, Hosseini SY, et al. ARID1A regulates E-cadherin expression in colorectal cancer cells: a promising candidate therapeutic target. Mol Biol Rep. 2021. https://doi.org/10.1007/s11033-021-06671-9.CrossRefPubMed

75.

Tomihara H, Carbone F, Perelli L, et al. Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress. Can Res. 2021. https://doi.org/10.1158/0008-5472.CAN-19-3922.CrossRef

76.

Huang L-Y, Zhao J, Chen H, et al. SCFFBW7-mediated degradation of Brg1 suppresses gastric cancer metastasis. Nat Commun. 2018. https://doi.org/10.1038/s41467-018-06038-y.CrossRefPubMedPubMedCentral

77.

Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020. https://doi.org/10.1038/s41568-019-0216-7.CrossRefPubMed

78.

Sun D, Teng F, Xing P, et al. ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer. Mol Med. 2021. https://doi.org/10.1186/s10020-021-00400-5.CrossRefPubMedPubMedCentral

79.

Kim Y-B, Ahn JM, Bae WJ, et al. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019. https://doi.org/10.1002/ijc.32140.CrossRefPubMedPubMedCentral

80.

Zhang S, Zhou Y-F, Cao J, et al. mTORC1 promotes ARID1A degradation and oncogenic chromatin remodeling in hepatocellular carcinoma. Can Res. 2021. https://doi.org/10.1158/0008-5472.CAN-21-0206.CrossRef

81.

Wang SC, Nassour I, Xiao S, et al. SWI/SNF component ARID1A restrains pancreatic neoplasia formation. Gut. 2019. https://doi.org/10.1136/gutjnl-2017-315490.CrossRefPubMed

82.

Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond). 2022. https://doi.org/10.1042/CS20201474.CrossRefPubMed

83.

Chang L, Azzolin L, Di Biagio D, et al. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature. 2018. https://doi.org/10.1038/s41586-018-0658-1.CrossRefPubMedPubMedCentral

84.

Hillmer RE, Link BA. The roles of hippo signaling transducers Yap and Taz in chromatin remodeling. Cells. 2019. https://doi.org/10.3390/cells8050502.CrossRefPubMedPubMedCentral

85.

Araki O, Tsuda M, Omatsu M, et al. Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway. Oncogene. 2023. https://doi.org/10.1038/s41388-023-02716-4.CrossRefPubMed

86.

Liu S, Cao W, Niu Y, et al. Single-PanIN-seq unveils that ARID1A deficiency promotes pancreatic tumorigenesis by attenuating KRAS-induced senescence. Elife. 2021. https://doi.org/10.7554/eLife.64204.CrossRefPubMedPubMedCentral

87.

Guo B, Friedland SC, Alexander W, et al. Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma. Cell Rep. 2022. https://doi.org/10.1016/j.celrep.2022.111253.CrossRefPubMedPubMedCentral

88.

Tokunaga R, Xiu J, Goldberg RM, et al. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. Eur J Cancer. 2020. https://doi.org/10.1016/j.ejca.2020.09.006.CrossRefPubMedPubMedCentral

89.

Kamori T, Oki E, Shimada Y, et al. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells. Cancer Reports. 2022. https://doi.org/10.1002/cnr2.1420.CrossRefPubMed

90.

Huang W, Li H, Shi X, et al. Characterization of genomic alterations in Chinese colorectal cancer patients. Jpn J Clin Oncol. 2021. https://doi.org/10.1093/jjco/hyaa182.CrossRefPubMed

91.

Kim SY, Shen Q, Son K, et al. SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer. Oncogene. 2021. https://doi.org/10.1038/s41388-021-01875-6.CrossRefPubMedPubMedCentral

92.

Yao B, Gui T, Zeng X, et al. PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome Med. 2021. https://doi.org/10.1186/s13073-021-00871-5.CrossRefPubMedPubMedCentral

93.

He D-D, Shang X-Y, Wang N, et al. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. Oncogene. 2022. https://doi.org/10.1038/s41388-022-02176-2.CrossRefPubMedPubMedCentral

94.

Wang R, Chen M, Ye X, et al. Role and potential clinical utility of ARID1A in gastrointestinal malignancy. Mutation Research/Reviews in Mutation Research. 2021. https://doi.org/10.1016/j.mrrev.2020.108360.CrossRefPubMed

95.

Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016. https://doi.org/10.1038/nm.4191.CrossRefPubMed

96.

Li Y, Yang X, Zhu W, et al. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases. Cancer Cell Int. 2022. https://doi.org/10.1186/s12935-022-02757-x.CrossRefPubMedPubMedCentral

97.

Peng L, Li J, Wu J, et al. A pan-cancer analysis of SMARCA4 alterations in human cancers. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.762598.CrossRefPubMedPubMedCentral

98.

Wei X-L, Wang D-S, Xi S-Y, et al. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol. 2014. https://doi.org/10.3748/wjg.v20.i48.18404.CrossRefPubMedPubMedCentral

Title: The role of SWI/SNF complexes in digestive system neoplasms
Authors: Hanyun Liang
Xin Zheng
Xiao Zhang
Yan Zhang
Jie Zheng
Publication date: 01-05-2024
Publisher: Springer US
Keywords: Colorectal Cancer
Colorectal Cancer
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Gastric Cancer
Gastric Cancer
Published in: Medical Oncology / Issue 5/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-024-02343-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives

Study of the effect of sFRP1 protein on molecules involved in the regulation of DNA methylation in CML cell line

Regulation of cancer progression by CK2: an emerging therapeutic target

Correction to: Gingerol and/or sorafenib attenuates the DAB-induced HCC and hepatic portal vein dilatation via ATG4/CASP3 and COIIV/COX-2/NF-κB expression

Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review

Ferroptosis is an effective strategy for cancer therapy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials